Skip to content
drillr.ai

LLY

Eli Lilly and Company

NYSE · USHealthcareDrug Manufacturers - General
$1146.85-2.74%

Price as of Jul 20, 2026

LLY news

Eli Lilly and Company news

A server-rendered, paginated timeline of the latest available company news.

  1. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

    BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. AtaiBeckley Inc. (Nasdaq – ATAI) Under the terms of the Merger Agreement, AtaiBeckley will be acquired by Eli Lilly and Company (NYSE - LLY) for $6.75 per share

    Globe Newswire ·

  2. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

    Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PR Newswire INDIANAPOLIS and NEW YORK, July 16, 2026 AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) an

    PR Newswire ·

  3. /C O R R E C T I O N -- Eli Lilly and Company/

    /C O R R E C T I O N -- Eli Lilly and Company/ PR Newswire INDIANAPOLIS, July 9, 2026 In the news release, Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment, issued July 9, 2026 by Eli Lilly and Company over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Lilly to present Alzheimer'

    PR Newswire ·

  4. Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment

    Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment PR Newswire INDIANAPOLIS, July 9, 2026 Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer's disea

    PR Newswire ·

  5. A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity

    Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre, expanding the home of its CXU™ regenerative tissue platform, a single technology the company is designing to scale across soft-tissue restoration markets spanning aesthetics and body contouring, wound care, and breast reconstruction. RENO, Nev., July 01, 2026 (GLOBE NEWSWIRE) -- Biotech Insider (https://www.globenewswire.c

    Globe Newswire ·

  6. Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

    Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China PR Newswire SAN FRANCISCO and SUZHOU, China, June 30, 2026 SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other

    PR Newswire ·

  7. Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

    Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy PR Newswire INDIANAPOLIS, June 26, 2026 The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology BRUIN CLL-313 is the first Phase 3 study to evaluate a non-cov

    PR Newswire ·

  8. Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI

    Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI PR Newswire GENEVA, June 26, 2026 New multi-country campaign launches in Geneva alongside the European Academy of Neurology Congress GENEVA, June 26, 2026 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY) launches The Memory Radio Station, a travelling public radio station and exhibition dedicated to the memories that makes us who we are – and to raise awar

    PR Newswire ·

  9. What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

    What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management PR Newswire INDIANAPOLIS, June 25, 2026 A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients beginning July 1 INDIANAPOLIS, June 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional det

    PR Newswire ·

  10. Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

    Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders PR Newswire INDIANAPOLIS, June 24, 2026 INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. "T

    PR Newswire ·

  11. Lilly declares third-quarter 2026 dividend

    Lilly declares third-quarter 2026 dividend PR Newswire INDIANAPOLIS, June 22, 2026 INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About Lilly Lilly is a medicine company turning science into healing to make life better

    PR Newswire ·

  12. Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

    Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL PR Newswire INDIANAPOLIS, June 14, 2026 BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor, reflects current practice patterns These data will be highlig

    PR Newswire ·

  13. Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

    Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting PR Newswire INDIANAPOLIS, June 13, 2026 INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with m

    PR Newswire ·

  14. Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable

    Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable PR Newswire INDIANAPOLIS, June 10, 2026 In the national campaign Watch This, O'Neal gets real about living with moderate obstructive sleep apnea (OSA) and the moment he decided to do something about it Zepbound(®) (tirzepatide) is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity and should b

    PR Newswire ·

  15. FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

    FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis PR Newswire INDIANAPOLIS, June 9, 2026 EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start INDIANAPOLIS, June 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one mai

    PR Newswire ·

  16. Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

    Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions Convatec (LSE:CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Company Foundation (Lilly Foundation), a tax-exempt private foundation supported by donations from Eli Lilly and Company (NYSE:LLY) have committed c.$5 million to Partners In Health (PIH), an international nonprofi

    Business Wire ·

  17. Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

    Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials PR Newswire INDIANAPOLIS, June 8, 2026 In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo delivered significant improvements in blood sugar and weight, with up to 68.6% and 69.1% of participants reaching an A1C goal of ≤6.5% resp

    PR Newswire ·

  18. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

    Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications PR Newswire INDIANAPOLIS, June 6, 2026 In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee oste

    PR Newswire ·

  19. Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

    Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting PR Newswire INDIANAPOLIS, June 2, 2026 Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be highlighted in a late-breaking oral presentation Ajax Therapeutics, which Lilly has agreed to acquire, will present the first clinical data

    PR Newswire ·

  20. Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

    Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer PR Newswire INDIANAPOLIS, May 31, 2026 Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of di

    PR Newswire ·